Researchers from the University of Gothenburg and the University of Copenhagen were invited by Science to review existing evidence on how GLP-1 drugs such as Ozempic and Mounjaro affect brain function. Animal studies suggest potential benefits for learning and memory, but findings in humans are mixed. In Novo Nordisk’s EVOKE and EVOKE+ trials, semaglutide did not slow the progression of early Alzheimer’s disease. Medical-record analyses have found only an association between lower dementia risk and type 2 diabetes. Whether early treatment can protect cognitive function remains to be confirmed through clinical trials.
Source:ScienceDaily · Read original article
Leave a Reply